BioRestorative Therapies, Inc. (BRTX) Stock

BioRestorative Therapies, Inc., based in Melville, New York, is a prominent life sciences company specializing in the advancement of regenerative medicine products and therapies utilizing cell and tissue protocols, particularly focusing on adult stem cells. Established in 1997 as Stem Cell Assurance, Inc. and rebranded as BioRestorative Therapies, Inc. in August 2011, the company is dedicated to pioneering innovative treatments for debilitating conditions.

The company's core developmental programs include the disc/spine program, known as brtxDisc, centered around its lead cell therapy candidate BRTX-100. This product is formulated from autologous cultured mesenchymal stem cells extracted from the patient's bone marrow. BRTX-100 has completed Phase 1 clinical trials for non-surgical treatment of painful lumbosacral disc disorders, demonstrating promising results in alleviating symptoms and improving patient outcomes. BioRestorative Therapies also advances its Metabolic Program, ThermoStem, a preclinical cell-based therapy targeting obesity and metabolic disorders using brown adipose-derived stem cells to generate brown adipose tissue.

Additionally, BioRestorative Therapies offers an investigational curved needle device designed to facilitate the delivery of cells and therapeutic materials to the spine and discs, enhancing treatment precision. The company has established strategic research and development collaborations with prominent entities such as Rohto Pharmaceutical Co., Ltd., Pfizer, Inc., and the University of Pennsylvania, underscoring its commitment to advancing cutting-edge therapies through collaborative innovation and rigorous scientific research. BioRestorative Therapies continues to lead in the field of regenerative medicine, striving to improve patient quality of life through innovative and effective treatments.